Complications of targeted drug therapies for solid malignancies: Manifestations and mechanisms

American Journal of Roentgenology

Volumn 200, Issue 3, 2013, Pages 475-483

  Abramson, Richard G ^a   Abramson, Vandana G ^b   Chan, Emily ^b   Horn, Leora ^b   Keedy, Vicki L ^b   Pao, William ^b   Sosman, Jeffrey A ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Drug toxicities; Imatinib; Ipilimumab; Targeted agents; Temsirolimus; Vemurafenib

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; IMATINIB; IPILIMUMAB; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SMALL MOLECULE TRANSPORT AGENT; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; VEMURAFENIB;

ACALCULOUS CHOLECYSTITIS; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANASARCA; ANGIOMYOLIPOMA; AORTA THROMBOSIS; ARTERY THROMBOSIS; ASCITES; BLEEDING; BRAIN HEMORRHAGE; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COLITIS; COLORECTAL CANCER; DELAYED HYPERSENSITIVITY; DERMATITIS; DERMATOFIBROSARCOMA PROTUBERANS; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; DYSPNEA; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; ENTERITIS; ENTEROCOLITIS; EPISTAXIS; ESOPHAGUS CANCER; FASCIITIS; FATTY LIVER; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HEMOPERITONEUM; HEMOPTYSIS; HEPATORENAL SYNDROME; HUMAN; HYPOPHYSITIS; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; INTESTINE ISCHEMIA; INTRACARDIAC THROMBOSIS; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER NECROSIS; LUNG EDEMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHADENOPATHY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENTERIC BLOOD VESSEL OCCLUSION; METASTATIC MELANOMA; MICROVASCULAR ISCHEMIA; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MYOSITIS; NEUROPATHY; OCCLUSIVE CEREBROVASCULAR DISEASE; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATITIS; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PNEUMATOSIS INTESTINALIS; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SOFT TISSUE SARCOMA; STOMACH CANCER; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THROMBOEMBOLISM; TOXIC HEPATITIS; TREATMENT INDICATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUBEROUS SCLEROSIS; TUMOR NECROSIS; VAGINA BLEEDING; WEBER CHRISTIAN PANNICULITIS; DRUG TOXICITY; NEOPLASM;

ANTINEOPLASTIC AGENTS; DRUG TOXICITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

MLCS; MLOWN;

EID: 84876015777     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9049     Document Type: Review

References (47)

1. Vanderbilt-Ingram Cancer Center (VICC) website. My cancer genome. www.mycancergenome. org. Accessed January 15, 2012
2. National Cancer Institute (NCI) website. Active clinical trials for targeted therapies. www.cancer.gov/cancertopics/understandingcancer/ targetedtherapies/activeclinicaltrials. Accessed December 13, 2011
3. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2:e17
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537
5. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003; 63:5054-5059
6. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24:2549-2556
7. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008; 177:1348-1357
8. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced nonsmall cell lung cancer treated with gefitinib. Lung Cancer 2004; 45:93-104
9. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006; 52:135-140
10. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011; 258:41-56
11. Liu W, Makrauer FL, Qamar AA, Janne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5:917-920
12. Howard SA, Krajewski KM, Thornton E, et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities -what radiologists should know. AJR 2012; 199:58-64
13. Widakowich C, de Castro G Jr., de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12:1443-1455
14. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676
15. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-5186
16. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10:559-568
17. Choi YI, Lee SH, Ahn BK, et al. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008; 40:33-35
18. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795
19. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009; 27:1405-1412
20. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239
21. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-982; discussion, 982
22. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006; 24:e48
23. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukoencephalopathy syndrome. Ann Oncol 2007; 18:1745-1747
24. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65:369-376
25. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44:173-175
26. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209-211
27. Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonates- associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007; 25:164-169
28. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007; 4:711-721
29. Morag Y, Morag-Hezroni M, Jamadar DA, et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. RadioGraphics 2009; 29:1971-1984
30. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312-3318
31. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124
32. Pezzilli R, Corinaldesi R, Morselli-Labate AM. Tyrosine kinase inhibitors and acute pancreatitis. JOP 2010; 11:291-293
33. de Lima Lopes G Jr., Rocha Lima CM. Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy 2007; 27:775-777
34. Gomez-Abuin G, Karam AA, Mezzadri NA, Bas CA. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer 2009; 7:62-63
35. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-2934
36. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. RadioGraphics 2006; 26:481-495
37. Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006; 81:189-192
38. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703
39. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
40. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215
41. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42:1875-1880
42. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77:1215-1220
43. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR 2011; 197:1293; [web]W992-W1000
44. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830
45. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR 2011; 197:283; [web]W241-W246
46. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR 2009; 30:1751-1753
47. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420